{"transactions":[{"id":734251,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37292,"kind":"person","name":"De La Rosa Abel","position":1,"cik":"0001825983","reported_name":"De La Rosa Abel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-17T17:19:32.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16800,"derivative":{"exercise_price":1.5,"exercise_date":"2027-06-16","expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":16800},"source":{"system":"sec-edgar","filing":"0001825983-26-000001","document":"form4-06172026_050629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000182598326000001/form4-06172026_050629.xml","form_type":"4"}},{"id":734252,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37293,"kind":"person","name":"Thomas John C","position":1,"cik":"0001424620","reported_name":"Thomas John C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-17T17:18:46.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16800,"derivative":{"exercise_price":1.5,"exercise_date":"2027-06-16","expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":16800},"source":{"system":"sec-edgar","filing":"0001424620-26-000002","document":"form4-06172026_050642.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000142462026000002/form4-06172026_050642.xml","form_type":"4"}},{"id":734248,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":15653,"kind":"person","name":"Whitley Richard James","position":1,"cik":"0001441661","reported_name":"Whitley Richard James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-17T17:17:40.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16800,"derivative":{"exercise_price":1.5,"exercise_date":"2027-06-16","expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":16800},"source":{"system":"sec-edgar","filing":"0001441661-26-000002","document":"form4-06172026_050636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000144166126000002/form4-06172026_050636.xml","form_type":"4"}},{"id":734250,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37291,"kind":"person","name":"Keefer David R","position":1,"cik":"0001825986","reported_name":"Keefer David R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-17T17:16:00.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16800,"derivative":{"exercise_price":1.5,"exercise_date":"2027-06-16","expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":16800},"source":{"system":"sec-edgar","filing":"0001825986-26-000002","document":"form4-06172026_050656.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000182598626000002/form4-06172026_050656.xml","form_type":"4"}},{"id":856008,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62305,"kind":"person","name":"Grosswald Ralph","position":1,"cik":"0001826084","reported_name":"Grosswald Ralph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP OF OPERATIONS"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-06T21:20:01.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter."}],"balance_after":82500,"derivative":{"exercise_price":2.86,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001826084-26-000002","document":"form4-03062026_090358.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000182608426000002/form4-03062026_090358.xml","form_type":"4"}},{"id":856007,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62304,"kind":"person","name":"Walsh Angela","position":1,"cik":"0001825987","reported_name":"Walsh Angela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-06T21:18:44.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter."}],"balance_after":82500,"derivative":{"exercise_price":2.86,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001825987-26-000002","document":"form4-03062026_090340.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000182598726000002/form4-03062026_090340.xml","form_type":"4"}},{"id":856006,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62303,"kind":"person","name":"Gendreau Roger Michael","position":1,"cik":"0001826131","reported_name":"Gendreau Roger Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-06T21:17:32.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter."}],"balance_after":82500,"derivative":{"exercise_price":2.86,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001826131-26-000002","document":"form4-03062026_090328.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000182613126000002/form4-03062026_090328.xml","form_type":"4"}},{"id":856003,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62302,"kind":"person","name":"Duncan Gregory Scott","position":1,"cik":"0001831127","reported_name":"Duncan Gregory Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-06T21:16:38.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter."}],"balance_after":330000,"derivative":{"exercise_price":2.86,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0001831127-26-000005","document":"form4-03062026_090335.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000183112726000005/form4-03062026_090335.xml","form_type":"4"}},{"id":979155,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62302,"kind":"person","name":"Duncan Gregory Scott","position":1,"cik":"0001831127","reported_name":"Duncan Gregory Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T21:05:15.000Z","date":"2025-12-04","kind":"grant","planned":false,"acquired":true,"shares":460000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on December 4, 2026 and 1/24th monthly thereafter."}],"balance_after":460000,"derivative":{"exercise_price":6.14,"expiration_date":"2035-12-04","underlying":"Common Stock","underlying_shares":460000},"source":{"system":"sec-edgar","filing":"0001831127-25-000005","document":"form4-12052025_041207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000183112725000005/form4-12052025_041207.xml","form_type":"4"}},{"id":979153,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62304,"kind":"person","name":"Walsh Angela","position":1,"cik":"0001825987","reported_name":"Walsh Angela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T21:05:12.000Z","date":"2025-12-04","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on December 4, 2026 and 1/24th monthly thereafter."}],"balance_after":150000,"derivative":{"exercise_price":6.14,"expiration_date":"2035-12-04","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001825987-25-000005","document":"form4-12052025_041205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000182598725000005/form4-12052025_041205.xml","form_type":"4"}},{"id":979154,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62305,"kind":"person","name":"Grosswald Ralph","position":1,"cik":"0001826084","reported_name":"Grosswald Ralph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP OF OPERATIONS"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T21:05:10.000Z","date":"2025-12-04","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on December 4, 2026 and 1/24th monthly thereafter."}],"balance_after":150000,"derivative":{"exercise_price":6.14,"expiration_date":"2035-12-04","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001826084-25-000005","document":"form4-12052025_041203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000182608425000005/form4-12052025_041203.xml","form_type":"4"}},{"id":979152,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62303,"kind":"person","name":"Gendreau Roger Michael","position":1,"cik":"0001826131","reported_name":"Gendreau Roger Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T21:05:07.000Z","date":"2025-12-04","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on December 4, 2026 and 1/24th monthly thereafter."}],"balance_after":150000,"derivative":{"exercise_price":6.14,"expiration_date":"2035-12-04","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001826131-25-000005","document":"form4-12052025_041201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000182613125000005/form4-12052025_041201.xml","form_type":"4"}},{"id":988958,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":72594,"kind":"person","name":"Sealbond Ltd","position":1,"cik":"0002040446","reported_name":"Sealbond Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":72595,"kind":"person","name":"Conjoint Inc.","position":2,"cik":"0002061651","reported_name":"Conjoint Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":26201,"kind":"organization","name":"CK Life Sciences Intl (Holdings) Inc","position":3,"cik":"0001297567","reported_name":"CK Life Sciences Intl (Holdings) Inc","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A-1 Preferred Stock","published_at":"2025-11-25T17:39:55.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":false,"shares":284.2638,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Conjoint Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares are held directly by Conjoint Inc., a Delaware corporation (\"Conjoint\"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company (\"Honglad\"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company (\"ENSO Resources\"). ENSO Resources is a wholly owned subsidiary of CKLS. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2842638},"source":{"system":"sec-edgar","filing":"0001104659-25-116066","document":"tm2532101-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2040446/000110465925116066/tm2532101-2_4seq1.xml","form_type":"4"}},{"id":988957,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":72594,"kind":"person","name":"Sealbond Ltd","position":1,"cik":"0002040446","reported_name":"Sealbond Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":72595,"kind":"person","name":"Conjoint Inc.","position":2,"cik":"0002061651","reported_name":"Conjoint Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":26201,"kind":"organization","name":"CK Life Sciences Intl (Holdings) Inc","position":3,"cik":"0001297567","reported_name":"CK Life Sciences Intl (Holdings) Inc","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A Preferred Stock","published_at":"2025-11-25T17:39:55.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":false,"shares":2161.095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F4","text":"Includes 52.7096 shares of Series A Preferred Stock previously issued to Sealbond as a payment-in-kind dividend that was exempt from Section 16 pursuant to Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Sealbond Limited, a British Virgin Islands limited company (\"Sealbond\"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company (\"Kamfull\"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company (\"Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability (\"CKLS\"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":21610950},"source":{"system":"sec-edgar","filing":"0001104659-25-116066","document":"tm2532101-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2040446/000110465925116066/tm2532101-2_4seq1.xml","form_type":"4"}},{"id":988956,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":72594,"kind":"person","name":"Sealbond Ltd","position":1,"cik":"0002040446","reported_name":"Sealbond Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":72595,"kind":"person","name":"Conjoint Inc.","position":2,"cik":"0002061651","reported_name":"Conjoint Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":26201,"kind":"organization","name":"CK Life Sciences Intl (Holdings) Inc","position":3,"cik":"0001297567","reported_name":"CK Life Sciences Intl (Holdings) Inc","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-25T17:39:55.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":true,"shares":2842638,"ownership":{"direct":false,"nature":"By Conjoint Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares are held directly by Conjoint Inc., a Delaware corporation (\"Conjoint\"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company (\"Honglad\"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company (\"ENSO Resources\"). ENSO Resources is a wholly owned subsidiary of CKLS. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":2842638,"source":{"system":"sec-edgar","filing":"0001104659-25-116066","document":"tm2532101-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040446/000110465925116066/tm2532101-2_4seq1.xml","form_type":"4"}},{"id":988955,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":72594,"kind":"person","name":"Sealbond Ltd","position":1,"cik":"0002040446","reported_name":"Sealbond Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":72595,"kind":"person","name":"Conjoint Inc.","position":2,"cik":"0002061651","reported_name":"Conjoint Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":26201,"kind":"organization","name":"CK Life Sciences Intl (Holdings) Inc","position":3,"cik":"0001297567","reported_name":"CK Life Sciences Intl (Holdings) Inc","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-25T17:39:55.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":true,"shares":21610950,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Sealbond Limited, a British Virgin Islands limited company (\"Sealbond\"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company (\"Kamfull\"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company (\"Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability (\"CKLS\"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":21822333,"source":{"system":"sec-edgar","filing":"0001104659-25-116066","document":"tm2532101-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040446/000110465925116066/tm2532101-2_4seq1.xml","form_type":"4"}},{"id":1097988,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62303,"kind":"person","name":"Gendreau Roger Michael","position":1,"cik":"0001826131","reported_name":"Gendreau Roger Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-01T18:11:12.000Z","date":"2025-06-27","kind":"grant","planned":false,"acquired":true,"shares":12075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on June 27, 2026 and 1/24th monthly thereafter."}],"balance_after":12075,"derivative":{"exercise_price":4.71,"expiration_date":"2035-06-27","underlying":"Common Stock","underlying_shares":12075},"source":{"system":"sec-edgar","filing":"0001415889-25-018653","document":"form4-07012025_060708.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925018653/form4-07012025_060708.xml","form_type":"4"}},{"id":1097986,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":15653,"kind":"person","name":"Whitley Richard James","position":1,"cik":"0001441661","reported_name":"Whitley Richard James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-01T18:07:30.000Z","date":"2025-06-27","kind":"grant","planned":false,"acquired":true,"shares":2362,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2362,"derivative":{"exercise_price":4.71,"exercise_date":"2026-06-27","expiration_date":"2035-06-27","underlying":"Common Stock","underlying_shares":2362},"source":{"system":"sec-edgar","filing":"0001415889-25-018651","document":"form4-07012025_060726.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925018651/form4-07012025_060726.xml","form_type":"4"}},{"id":1097987,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62305,"kind":"person","name":"Grosswald Ralph","position":1,"cik":"0001826084","reported_name":"Grosswald Ralph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP OF OPERATIONS"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-01T18:05:00.000Z","date":"2025-06-27","kind":"grant","planned":false,"acquired":true,"shares":12075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on June 27, 2026 and 1/24th monthly thereafter."}],"balance_after":12075,"derivative":{"exercise_price":4.71,"expiration_date":"2035-06-27","underlying":"Common Stock","underlying_shares":12075},"source":{"system":"sec-edgar","filing":"0001415889-25-018648","document":"form4-07012025_060757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925018648/form4-07012025_060757.xml","form_type":"4"}},{"id":1097985,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37293,"kind":"person","name":"Thomas John C","position":1,"cik":"0001424620","reported_name":"Thomas John C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-01T18:02:30.000Z","date":"2025-06-27","kind":"grant","planned":false,"acquired":true,"shares":2362,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2362,"derivative":{"exercise_price":4.71,"exercise_date":"2026-06-27","expiration_date":"2035-06-27","underlying":"Common Stock","underlying_shares":2362},"source":{"system":"sec-edgar","filing":"0001415889-25-018645","document":"form4-07012025_060727.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925018645/form4-07012025_060727.xml","form_type":"4"}},{"id":1097984,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62302,"kind":"person","name":"Duncan Gregory Scott","position":1,"cik":"0001831127","reported_name":"Duncan Gregory Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-01T18:00:33.000Z","date":"2025-06-27","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on June 27, 2026 and 1/24th monthly thereafter."}],"balance_after":40000,"derivative":{"exercise_price":4.71,"expiration_date":"2035-06-27","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-25-018643","document":"form4-07012025_060730.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925018643/form4-07012025_060730.xml","form_type":"4"}},{"id":1097983,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37291,"kind":"person","name":"Keefer David R","position":1,"cik":"0001825986","reported_name":"Keefer David R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-01T17:58:11.000Z","date":"2025-06-27","kind":"grant","planned":false,"acquired":true,"shares":2362,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2362,"derivative":{"exercise_price":4.71,"exercise_date":"2026-06-27","expiration_date":"2035-06-27","underlying":"Common Stock","underlying_shares":2362},"source":{"system":"sec-edgar","filing":"0001415889-25-018640","document":"form4-07012025_050707.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925018640/form4-07012025_050707.xml","form_type":"4"}},{"id":1097977,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62304,"kind":"person","name":"Walsh Angela","position":1,"cik":"0001825987","reported_name":"Walsh Angela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-01T17:56:11.000Z","date":"2025-06-27","kind":"grant","planned":false,"acquired":true,"shares":12075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on June 27, 2026 and 1/24th monthly thereafter."}],"balance_after":12075,"derivative":{"exercise_price":4.71,"expiration_date":"2035-06-27","underlying":"Common Stock","underlying_shares":12075},"source":{"system":"sec-edgar","filing":"0001415889-25-018638","document":"form4-07012025_050708.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925018638/form4-07012025_050708.xml","form_type":"4"}},{"id":1097982,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37292,"kind":"person","name":"De La Rosa Abel","position":1,"cik":"0001825983","reported_name":"De La Rosa Abel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-01T17:52:24.000Z","date":"2025-06-27","kind":"grant","planned":false,"acquired":true,"shares":2362,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2362,"derivative":{"exercise_price":4.71,"exercise_date":"2026-06-27","expiration_date":"2035-06-27","underlying":"Common Stock","underlying_shares":2362},"source":{"system":"sec-edgar","filing":"0001415889-25-018635","document":"form4-07012025_050721.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925018635/form4-07012025_050721.xml","form_type":"4"}},{"id":1103920,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":15653,"kind":"person","name":"Whitley Richard James","position":1,"cik":"0001441661","reported_name":"Whitley Richard James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T16:04:13.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":210,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":420,"derivative":{"exercise_price":4.8,"exercise_date":"2026-06-18","expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":210},"source":{"system":"sec-edgar","filing":"0001415889-25-017940","document":"form4-06232025_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925017940/form4-06232025_040610.xml","form_type":"4"}},{"id":1103919,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":15653,"kind":"person","name":"Whitley Richard James","position":1,"cik":"0001441661","reported_name":"Whitley Richard James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T16:04:13.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":210,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":210,"derivative":{"exercise_price":4.8,"exercise_date":"2026-06-18","expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":210},"source":{"system":"sec-edgar","filing":"0001415889-25-017940","document":"form4-06232025_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925017940/form4-06232025_040610.xml","form_type":"4"}},{"id":1103915,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37291,"kind":"person","name":"Keefer David R","position":1,"cik":"0001825986","reported_name":"Keefer David R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T16:02:49.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":210,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":420,"derivative":{"exercise_price":4.8,"exercise_date":"2026-06-18","expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":210},"source":{"system":"sec-edgar","filing":"0001415889-25-017938","document":"form4-06232025_040645.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925017938/form4-06232025_040645.xml","form_type":"4"}},{"id":1103914,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37291,"kind":"person","name":"Keefer David R","position":1,"cik":"0001825986","reported_name":"Keefer David R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T16:02:49.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":210,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":210,"derivative":{"exercise_price":4.8,"exercise_date":"2026-06-18","expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":210},"source":{"system":"sec-edgar","filing":"0001415889-25-017938","document":"form4-06232025_040645.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925017938/form4-06232025_040645.xml","form_type":"4"}},{"id":1103913,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37293,"kind":"person","name":"Thomas John C","position":1,"cik":"0001424620","reported_name":"Thomas John C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T15:59:08.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":210,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":420,"derivative":{"exercise_price":4.8,"exercise_date":"2026-06-18","expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":210},"source":{"system":"sec-edgar","filing":"0001415889-25-017934","document":"form4-06232025_030604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925017934/form4-06232025_030604.xml","form_type":"4"}},{"id":1103912,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37293,"kind":"person","name":"Thomas John C","position":1,"cik":"0001424620","reported_name":"Thomas John C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T15:59:08.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":210,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":210,"derivative":{"exercise_price":4.8,"exercise_date":"2026-06-18","expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":210},"source":{"system":"sec-edgar","filing":"0001415889-25-017934","document":"form4-06232025_030604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925017934/form4-06232025_030604.xml","form_type":"4"}},{"id":1103911,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37292,"kind":"person","name":"De La Rosa Abel","position":1,"cik":"0001825983","reported_name":"De La Rosa Abel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T15:57:31.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":210,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":420,"derivative":{"exercise_price":4.8,"exercise_date":"2026-06-18","expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":210},"source":{"system":"sec-edgar","filing":"0001415889-25-017932","document":"form4-06232025_030627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925017932/form4-06232025_030627.xml","form_type":"4"}},{"id":1103910,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37292,"kind":"person","name":"De La Rosa Abel","position":1,"cik":"0001825983","reported_name":"De La Rosa Abel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T15:57:31.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":210,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":210,"derivative":{"exercise_price":4.8,"exercise_date":"2026-06-18","expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":210},"source":{"system":"sec-edgar","filing":"0001415889-25-017932","document":"form4-06232025_030627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588925017932/form4-06232025_030627.xml","form_type":"4"}},{"id":1203913,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":26201,"kind":"organization","name":"CK Life Sciences Intl (Holdings) Inc","position":1,"cik":"0001297567","reported_name":"CK Life Sciences Intl (Holdings) Inc","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A-1 Preferred Stock","published_at":"2025-03-18T01:07:18.000Z","date":"2025-03-12","kind":"grant","planned":false,"acquired":true,"shares":284.2638,"price":7.01,"value":1992.689238,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Following stockholder approval of the conversion of the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of the Series A-1 Preferred Stock will be convertible into 10,000 shares of Common Stock, subject to waiver by Conjoint, as the direct holder of the shares, of a beneficial ownership limitation of 19.99% of the outstanding Common Stock. The shares of Series A-1 Preferred Stock have no expiration date. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On March 12, 2025, Conjoint entered into a Debt Exchange and Cancellation Agreement with the Issuer pursuant to which $19,500,000 in principal amount of all loans made to the Issuer under a Loan Agreement, dated October 7, 2024 (the \"Loan Agreement\"), between Conjoint and the Issuer, along with accrued interest through March 12, 2025 (as of such date, an aggregate of $19,926,891), was deemed repaid and all of the Issuer's obligations under the Loan Agreement with respect to the principal amount and accrued interest was satisfied in full and cancelled in exchange for 284.2638 shares of Series A-1 Preferred Stock, based on a price per underlying share of Common Stock of $7.01. This transaction involved an acquisition of shares in connection with a debt previously contracted."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 12, 2025, Conjoint entered into a Debt Exchange and Cancellation Agreement with the Issuer pursuant to which $19,500,000 in principal amount of all loans made to the Issuer under a Loan Agreement, dated October 7, 2024 (the \"Loan Agreement\"), between Conjoint and the Issuer, along with accrued interest through March 12, 2025 (as of such date, an aggregate of $19,926,891), was deemed repaid and all of the Issuer's obligations under the Loan Agreement with respect to the principal amount and accrued interest was satisfied in full and cancelled in exchange for 284.2638 shares of Series A-1 Preferred Stock, based on a price per underlying share of Common Stock of $7.01. This transaction involved an acquisition of shares in connection with a debt previously contracted."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Following stockholder approval of the conversion of the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of the Series A-1 Preferred Stock will be convertible into 10,000 shares of Common Stock, subject to waiver by Conjoint, as the direct holder of the shares, of a beneficial ownership limitation of 19.99% of the outstanding Common Stock. The shares of Series A-1 Preferred Stock have no expiration date. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Following stockholder approval of the conversion of the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of the Series A-1 Preferred Stock will be convertible into 10,000 shares of Common Stock, subject to waiver by Conjoint, as the direct holder of the shares, of a beneficial ownership limitation of 19.99% of the outstanding Common Stock. The shares of Series A-1 Preferred Stock have no expiration date. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held directly by Conjoint Inc., a Delaware corporation (\"Conjoint\"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company (\"Honglad\"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company (\"ENSO Resources\"). ENSO Resources is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability (\"CKLS\"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":284.2638,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2842638},"source":{"system":"sec-edgar","filing":"0001104659-25-024577","document":"tm259598-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000110465925024577/tm259598-1_4seq1.xml","form_type":"4"}},{"id":1612524,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-28T18:14:56.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":2917,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on February 26, 2025, one year following the grant date."}],"balance_after":2917,"derivative":{"exercise_price":0.357,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":2917},"source":{"system":"sec-edgar","filing":"0001415889-24-005686","document":"form4-02282024_060247.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588924005686/form4-02282024_060247.xml","form_type":"4"}},{"id":1612523,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37293,"kind":"person","name":"Thomas John C","position":1,"cik":"0001424620","reported_name":"Thomas John C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-28T18:09:44.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":4167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on February 26, 2025, one year following the grant date."}],"balance_after":4167,"derivative":{"exercise_price":0.357,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":4167},"source":{"system":"sec-edgar","filing":"0001415889-24-005684","document":"form4-02282024_060238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588924005684/form4-02282024_060238.xml","form_type":"4"}},{"id":1612520,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":15653,"kind":"person","name":"Whitley Richard James","position":1,"cik":"0001441661","reported_name":"Whitley Richard James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-28T18:04:06.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on February 26, 2025, one year following the grant date."}],"balance_after":4000,"derivative":{"exercise_price":0.357,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001415889-24-005681","document":"form4-02282024_060200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588924005681/form4-02282024_060200.xml","form_type":"4"}},{"id":1612522,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37291,"kind":"person","name":"Keefer David R","position":1,"cik":"0001825986","reported_name":"Keefer David R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-28T18:01:38.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":4709,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on February 26, 2025, one year following the grant date."}],"balance_after":4709,"derivative":{"exercise_price":0.357,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":4709},"source":{"system":"sec-edgar","filing":"0001415889-24-005679","document":"form4-02282024_060230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588924005679/form4-02282024_060230.xml","form_type":"4"}},{"id":1612521,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93755,"kind":"person","name":"Burch Richard Alan","position":1,"cik":"0001837084","reported_name":"Burch Richard Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-28T17:56:28.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":2917,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on February 26, 2025, one year following the grant date."}],"balance_after":2917,"derivative":{"exercise_price":0.357,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":2917},"source":{"system":"sec-edgar","filing":"0001415889-24-005676","document":"form4-02282024_050222.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588924005676/form4-02282024_050222.xml","form_type":"4"}},{"id":1612519,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37292,"kind":"person","name":"De La Rosa Abel","position":1,"cik":"0001825983","reported_name":"De La Rosa Abel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-28T17:54:20.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":3959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on February 26, 2025, one year following the grant date."}],"balance_after":3959,"derivative":{"exercise_price":0.357,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":3959},"source":{"system":"sec-edgar","filing":"0001415889-24-005674","document":"form4-02282024_050213.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588924005674/form4-02282024_050213.xml","form_type":"4"}},{"id":1612518,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62304,"kind":"person","name":"Walsh Angela","position":1,"cik":"0001825987","reported_name":"Walsh Angela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP OF FINANCE"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-28T17:51:34.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":63618,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on February 26, 2025, one year following the grant date."}],"balance_after":63618,"derivative":{"exercise_price":0.357,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":63618},"source":{"system":"sec-edgar","filing":"0001415889-24-005672","document":"form4-02282024_050228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588924005672/form4-02282024_050228.xml","form_type":"4"}},{"id":1612517,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62305,"kind":"person","name":"Grosswald Ralph","position":1,"cik":"0001826084","reported_name":"Grosswald Ralph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP OF OPERATIONS"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-28T17:47:41.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":62568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on February 26, 2025, one year following the grant date."}],"balance_after":62568,"derivative":{"exercise_price":0.357,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":62568},"source":{"system":"sec-edgar","filing":"0001415889-24-005670","document":"form4-02282024_050234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588924005670/form4-02282024_050234.xml","form_type":"4"}},{"id":1612516,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62303,"kind":"person","name":"Gendreau Roger Michael","position":1,"cik":"0001826131","reported_name":"Gendreau Roger Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-28T17:43:15.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":88085,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on February 26, 2025, one year following the grant date."}],"balance_after":88085,"derivative":{"exercise_price":0.357,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":88085},"source":{"system":"sec-edgar","filing":"0001415889-24-005668","document":"form4-02282024_050208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588924005668/form4-02282024_050208.xml","form_type":"4"}},{"id":1612515,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62302,"kind":"person","name":"Duncan Gregory Scott","position":1,"cik":"0001831127","reported_name":"Duncan Gregory Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-28T17:40:36.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":138835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on February 26, 2025, one year following the grant date."}],"balance_after":138835,"derivative":{"exercise_price":0.357,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":138835},"source":{"system":"sec-edgar","filing":"0001415889-24-005666","document":"form4-02282024_050227.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588924005666/form4-02282024_050227.xml","form_type":"4"}},{"id":1799764,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-22T19:57:39.000Z","date":"2023-08-21","kind":"purchase","planned":false,"acquired":true,"shares":15335,"price":1.3037,"value":19992.2395,"ownership":{"direct":false,"nature":"401 (k) Account"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.26 to $1.36, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. (\"Virios\"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee."}],"balance_after":52045,"source":{"system":"sec-edgar","filing":"0001415889-23-012474","document":"form4-08222023_070830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588923012474/form4-08222023_070830.xml","form_type":"4"}},{"id":1802034,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62302,"kind":"person","name":"Duncan Gregory Scott","position":1,"cik":"0001831127","reported_name":"Duncan Gregory Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-08-18T11:05:06.000Z","date":"2023-08-17","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":1.2498,"value":31245.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.00 to $1.25, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. (\"Virios\"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":57461,"source":{"system":"sec-edgar","filing":"0001415889-23-012375","document":"form4-08182023_070801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588923012375/form4-08182023_070801.xml","form_type":"4"}},{"id":1849753,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37291,"kind":"person","name":"Keefer David R","position":1,"cik":"0001825986","reported_name":"Keefer David R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T18:06:18.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on June 15, 2024, one year following the grant date."}],"balance_after":5250,"derivative":{"exercise_price":1.85,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001415889-23-009993","document":"form4-06202023_060614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588923009993/form4-06202023_060614.xml","form_type":"4"}},{"id":1849752,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37292,"kind":"person","name":"De La Rosa Abel","position":1,"cik":"0001825983","reported_name":"De La Rosa Abel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T18:03:54.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on June 15, 2024, one year following the grant date."}],"balance_after":5250,"derivative":{"exercise_price":1.85,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001415889-23-009991","document":"form4-06202023_060650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588923009991/form4-06202023_060650.xml","form_type":"4"}},{"id":1849751,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37293,"kind":"person","name":"Thomas John C","position":1,"cik":"0001424620","reported_name":"Thomas John C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T18:01:31.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on June 15, 2024, one year following the grant date."}],"balance_after":5250,"derivative":{"exercise_price":1.85,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001415889-23-009989","document":"form4-06202023_060625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588923009989/form4-06202023_060625.xml","form_type":"4"}},{"id":1849750,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93755,"kind":"person","name":"Burch Richard Alan","position":1,"cik":"0001837084","reported_name":"Burch Richard Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T17:58:36.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on June 15, 2024, one year following the grant date."}],"balance_after":5250,"derivative":{"exercise_price":1.85,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001415889-23-009987","document":"form4-06202023_050630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588923009987/form4-06202023_050630.xml","form_type":"4"}},{"id":1849749,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":15653,"kind":"person","name":"Whitley Richard James","position":1,"cik":"0001441661","reported_name":"Whitley Richard James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T17:56:00.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on June 15, 2024, one year following the grant date."}],"balance_after":5250,"derivative":{"exercise_price":1.85,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001415889-23-009985","document":"form4-06202023_050656.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588923009985/form4-06202023_050656.xml","form_type":"4"}},{"id":1849748,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T17:53:39.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on June 14, 2024, one year following the grant date."}],"balance_after":5250,"derivative":{"exercise_price":1.85,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001415889-23-009983","document":"form4-06202023_050635.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588923009983/form4-06202023_050635.xml","form_type":"4"}},{"id":2013745,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62302,"kind":"person","name":"Duncan Gregory Scott","position":1,"cik":"0001831127","reported_name":"Duncan Gregory Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-15T17:54:16.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":410000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person filed a Form 4 on December 14, 2022 which incorrectly reported that on December 12, 2022 he was granted 480,000 Stock Options. This Form 4 amendment is being filed for the purpose of amending and restating the Form 4 to reflect that the reporting person was granted 410,000 Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests one-third on December 12, 2023 and 1/24th monthly thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The reporting person filed a Form 4 on December 14, 2022 which incorrectly reported that on December 12, 2022 he was granted 480,000 Stock Options. This Form 4 amendment is being filed for the purpose of amending and restating the Form 4 to reflect that the reporting person was granted 410,000 Stock Options."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person filed a Form 4 on December 14, 2022 which incorrectly reported that on December 12, 2022 he was granted 480,000 Stock Options. This Form 4 amendment is being filed for the purpose of amending and restating the Form 4 to reflect that the reporting person was granted 410,000 Stock Options."}],"balance_after":410000,"derivative":{"exercise_price":0.2789,"expiration_date":"2032-12-12","underlying":"Common Stock","underlying_shares":410000},"source":{"system":"sec-edgar","filing":"0001415889-23-002583","document":"form4a-02152023_050206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588923002583/form4a-02152023_050206.xml","form_type":"4/A","original_submission_date":"2022-12-14"}},{"id":2086620,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62302,"kind":"person","name":"Duncan Gregory Scott","position":1,"cik":"0001831127","reported_name":"Duncan Gregory Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-14T23:33:01.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":480000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on December 12, 2023 and 1/24th monthly thereafter."}],"balance_after":480000,"derivative":{"exercise_price":0.2789,"expiration_date":"2032-12-12","underlying":"Common Stock","underlying_shares":480000},"source":{"system":"sec-edgar","filing":"0001415889-22-012561","document":"form4-12142022_111237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922012561/form4-12142022_111237.xml","form_type":"4"}},{"id":2086619,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62304,"kind":"person","name":"Walsh Angela","position":1,"cik":"0001825987","reported_name":"Walsh Angela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP OF FINANCE"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-14T23:32:16.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on December 12, 2023 and 1/24th monthly thereafter."}],"balance_after":80000,"derivative":{"exercise_price":0.2789,"expiration_date":"2032-12-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001415889-22-012560","document":"form4-12142022_111252.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922012560/form4-12142022_111252.xml","form_type":"4"}},{"id":2086618,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62305,"kind":"person","name":"Grosswald Ralph","position":1,"cik":"0001826084","reported_name":"Grosswald Ralph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP OF OPERATIONS"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-14T23:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on December 12, 2023 and 1/24th monthly thereafter."}],"balance_after":80000,"derivative":{"exercise_price":0.2789,"expiration_date":"2032-12-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001415889-22-012559","document":"form4-12142022_111254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922012559/form4-12142022_111254.xml","form_type":"4"}},{"id":2086617,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62303,"kind":"person","name":"Gendreau Roger Michael","position":1,"cik":"0001826131","reported_name":"Gendreau Roger Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-14T23:30:25.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on December 12, 2023 and 1/24th monthly thereafter."}],"balance_after":80000,"derivative":{"exercise_price":0.2789,"expiration_date":"2032-12-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001415889-22-012558","document":"form4-12142022_111202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922012558/form4-12142022_111202.xml","form_type":"4"}},{"id":2089849,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":15653,"kind":"person","name":"Whitley Richard James","position":1,"cik":"0001441661","reported_name":"Whitley Richard James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-12T18:39:49.000Z","date":"2022-12-08","kind":"sale","acquired":false,"shares":1800,"price":0.2591,"value":466.38,"ownership":{"direct":true},"balance_after":700,"source":{"system":"sec-edgar","filing":"0001415889-22-012370","document":"form4-12122022_061240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922012370/form4-12122022_061240.xml","form_type":"4"}},{"id":2218780,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":15653,"kind":"person","name":"Whitley Richard James","position":1,"cik":"0001441661","reported_name":"Whitley Richard James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-30T18:09:58.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on June 23, 2023, one year following the grant date."}],"balance_after":5250,"derivative":{"exercise_price":4.23,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001415889-22-007096","document":"form4-06302022_110649.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922007096/form4-06302022_110649.xml","form_type":"4"}},{"id":2218779,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-30T18:08:11.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on June 23, 2023, one year following the grant date."}],"balance_after":5250,"derivative":{"exercise_price":4.23,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001415889-22-007094","document":"form4-06302022_110603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922007094/form4-06302022_110603.xml","form_type":"4"}},{"id":2218778,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93755,"kind":"person","name":"Burch Richard Alan","position":1,"cik":"0001837084","reported_name":"Burch Richard Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-30T18:05:45.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on June 23, 2023, one year following the grant date."}],"balance_after":5250,"derivative":{"exercise_price":4.23,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001415889-22-007092","document":"form4-06302022_110636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922007092/form4-06302022_110636.xml","form_type":"4"}},{"id":2218777,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37291,"kind":"person","name":"Keefer David R","position":1,"cik":"0001825986","reported_name":"Keefer David R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-30T18:03:23.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on June 23, 2023, one year following the grant date."}],"balance_after":5250,"derivative":{"exercise_price":4.23,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001415889-22-007089","document":"form4-06302022_110615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922007089/form4-06302022_110615.xml","form_type":"4"}},{"id":2218776,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37293,"kind":"person","name":"Thomas John C","position":1,"cik":"0001424620","reported_name":"Thomas John C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-30T18:01:46.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on June 23, 2023, one year following the grant date."}],"balance_after":5250,"derivative":{"exercise_price":4.23,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001415889-22-007087","document":"form4-06302022_110637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922007087/form4-06302022_110637.xml","form_type":"4"}},{"id":2218775,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37292,"kind":"person","name":"De La Rosa Abel","position":1,"cik":"0001825983","reported_name":"De La Rosa Abel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-30T17:59:52.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest 100% on June 23, 2023, one year following the grant date."}],"balance_after":5250,"derivative":{"exercise_price":4.23,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001415889-22-007085","document":"form4-06302022_100643.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922007085/form4-06302022_100643.xml","form_type":"4"}},{"id":2218774,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62303,"kind":"person","name":"Gendreau Roger Michael","position":1,"cik":"0001826131","reported_name":"Gendreau Roger Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2022-06-30T17:53:44.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on June 23, 2023 and 1/24th monthly thereafter."}],"balance_after":40000,"derivative":{"exercise_price":4.23,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-22-007083","document":"form4-06302022_100635.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922007083/form4-06302022_100635.xml","form_type":"4"}},{"id":2218773,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62305,"kind":"person","name":"Grosswald Ralph","position":1,"cik":"0001826084","reported_name":"Grosswald Ralph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP OF OPERATIONS"}}],"security":"Stock Option (right to buy)","published_at":"2022-06-30T17:43:10.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on June 23, 2023 and 1/24th monthly thereafter."}],"balance_after":40000,"derivative":{"exercise_price":4.23,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-22-007080","document":"form4-06302022_100659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922007080/form4-06302022_100659.xml","form_type":"4"}},{"id":2218771,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62304,"kind":"person","name":"Walsh Angela","position":1,"cik":"0001825987","reported_name":"Walsh Angela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP OF FINANCE"}}],"security":"Stock Option (right to buy)","published_at":"2022-06-30T17:40:50.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on June 23, 2023 and 1/24th monthly thereafter."}],"balance_after":40000,"derivative":{"exercise_price":4.23,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-22-007078","document":"form4-06302022_100642.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922007078/form4-06302022_100642.xml","form_type":"4"}},{"id":2218772,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62302,"kind":"person","name":"Duncan Gregory Scott","position":1,"cik":"0001831127","reported_name":"Duncan Gregory Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2022-06-30T17:38:55.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on June 23, 2023 and 1/24th monthly thereafter."}],"balance_after":90000,"derivative":{"exercise_price":4.23,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001415889-22-007076","document":"form4-06302022_100647.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922007076/form4-06302022_100647.xml","form_type":"4"}},{"id":2258494,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62304,"kind":"person","name":"Walsh Angela","position":1,"cik":"0001825987","reported_name":"Walsh Angela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP OF FINANCE"}}],"security":"Common Stock","published_at":"2022-05-24T18:53:44.000Z","date":"2022-05-23","kind":"purchase","acquired":true,"shares":2000,"price":4.575,"value":9150.0,"ownership":{"direct":false,"nature":"By IRA"},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001415889-22-005575","document":"form4-05242022_110533.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922005575/form4-05242022_110533.xml","form_type":"4"}},{"id":2258493,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62302,"kind":"person","name":"Duncan Gregory Scott","position":1,"cik":"0001831127","reported_name":"Duncan Gregory Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-05-24T14:24:56.000Z","date":"2022-05-23","kind":"purchase","acquired":true,"shares":7500,"price":4.52,"value":33900.0,"ownership":{"direct":true},"balance_after":32461,"source":{"system":"sec-edgar","filing":"0001415889-22-005567","document":"form4-05242022_070548.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922005567/form4-05242022_070548.xml","form_type":"4"}},{"id":2263951,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":15653,"kind":"person","name":"Whitley Richard James","position":1,"cik":"0001441661","reported_name":"Whitley Richard James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-19T15:48:41.000Z","date":"2022-05-18","kind":"purchase","acquired":true,"shares":500,"price":4.525,"value":2262.5,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001415889-22-005275","document":"form4-05192022_080533.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922005275/form4-05192022_080533.xml","form_type":"4"}},{"id":2263949,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-19T15:44:58.000Z","date":"2022-05-18","kind":"purchase","acquired":true,"shares":241,"price":4.5,"value":1084.5,"ownership":{"direct":false,"nature":"401 (k) Account"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee."}],"balance_after":36710,"source":{"system":"sec-edgar","filing":"0001415889-22-005272","document":"form4-05192022_080545.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922005272/form4-05192022_080545.xml","form_type":"4"}},{"id":2265921,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-18T15:24:25.000Z","date":"2022-05-17","kind":"purchase","acquired":true,"shares":13450,"price":4.3802,"value":58913.69,"ownership":{"direct":false,"nature":"401 (k) Account"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.94 to $4.57, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. (\"Virios\"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee."}],"balance_after":36469,"source":{"system":"sec-edgar","filing":"0001415889-22-005214","document":"form4-05182022_080517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922005214/form4-05182022_080517.xml","form_type":"4"}},{"id":2314291,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-30T15:55:24.000Z","date":"2022-03-29","kind":"purchase","acquired":true,"shares":600,"price":4.9408,"value":2964.48,"ownership":{"direct":false,"nature":"401 (k) Account"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.94 to $4.97, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. (\"Virios\"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee."}],"balance_after":23019,"source":{"system":"sec-edgar","filing":"0001415889-22-003465","document":"form4-03302022_080315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922003465/form4-03302022_080315.xml","form_type":"4"}},{"id":2318967,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-24T18:52:33.000Z","date":"2022-03-23","kind":"purchase","acquired":true,"shares":2197,"price":5.4627,"value":12001.5519,"ownership":{"direct":false,"nature":"401 (k) Account"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.37 to $5.48, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. (\"Virios\"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects corrected holdings, as prior reports incorrectly understated indirect holdings and overstated direct holdings, by 1,500 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee."}],"balance_after":22419,"source":{"system":"sec-edgar","filing":"0001415889-22-003314","document":"form4-03242022_110324.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922003314/form4-03242022_110324.xml","form_type":"4"}},{"id":2422698,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T20:30:24.000Z","date":"2022-01-27","kind":"purchase","acquired":true,"shares":4180,"price":5.9803,"value":24997.654,"ownership":{"direct":false,"nature":"401 (k) Account"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.80 to $6.27, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. (\"Virios\"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee."}],"balance_after":18722,"source":{"system":"sec-edgar","filing":"0001415889-22-000846","document":"form4-01282022_120112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922000846/form4-01282022_120112.xml","form_type":"4"}},{"id":2440241,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37292,"kind":"person","name":"De La Rosa Abel","position":1,"cik":"0001825983","reported_name":"De La Rosa Abel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-07T22:24:26.000Z","date":"2022-01-07","kind":"purchase","acquired":true,"shares":4000,"price":5.896,"value":23584.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.8375 to $6.00, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. (\"Virios\"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":4000,"source":{"system":"sec-edgar","filing":"0001415889-22-000462","document":"form4-01072022_020119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922000462/form4-01072022_020119.xml","form_type":"4"}},{"id":2440240,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":15653,"kind":"person","name":"Whitley Richard James","position":1,"cik":"0001441661","reported_name":"Whitley Richard James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-07T18:14:42.000Z","date":"2022-01-06","kind":"purchase","acquired":true,"shares":1800,"price":5.72,"value":10296.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001415889-22-000447","document":"form4-01072022_100133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922000447/form4-01072022_100133.xml","form_type":"4"}},{"id":2444387,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37291,"kind":"person","name":"Keefer David R","position":1,"cik":"0001825986","reported_name":"Keefer David R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-05T20:12:06.000Z","date":"2022-01-04","kind":"purchase","acquired":true,"shares":5000,"price":5.795,"value":28975.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.75 to $5.80, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. (\"Virios\"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001415889-22-000350","document":"form4-01052022_120151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922000350/form4-01052022_120151.xml","form_type":"4"}},{"id":2449897,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T20:23:08.000Z","date":"2022-01-03","kind":"purchase","acquired":true,"shares":2215,"price":5.4329,"value":12033.8735,"ownership":{"direct":false,"nature":"401 (k) Account"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.20 to $5.70, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. (\"Virios\"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee."}],"balance_after":14542,"source":{"system":"sec-edgar","filing":"0001415889-22-000167","document":"form4-01042022_120157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922000167/form4-01042022_120157.xml","form_type":"4"}},{"id":2449896,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37293,"kind":"person","name":"Thomas John C","position":1,"cik":"0001424620","reported_name":"Thomas John C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T20:19:57.000Z","date":"2022-01-04","kind":"purchase","acquired":true,"shares":1000,"price":5.65,"value":5650.0,"ownership":{"direct":true},"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001415889-22-000165","document":"form4-01042022_120143.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588922000165/form4-01042022_120143.xml","form_type":"4"}},{"id":2459716,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":15653,"kind":"person","name":"Whitley Richard James","position":1,"cik":"0001441661","reported_name":"Whitley Richard James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-23T20:59:47.000Z","date":"2021-12-23","kind":"purchase","acquired":true,"shares":200,"price":5.725,"value":1145.0,"ownership":{"direct":true},"balance_after":200,"source":{"system":"sec-edgar","filing":"0001415889-21-006204","document":"form4-12232021_121238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588921006204/form4-12232021_121238.xml","form_type":"4"}},{"id":2461265,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-22T18:28:40.000Z","date":"2021-12-21","kind":"purchase","acquired":true,"shares":8827,"price":5.6641,"value":49997.0107,"ownership":{"direct":false,"nature":"401 (k) Account"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.375 to $5.8799, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. (\"Virios\"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee."}],"balance_after":12327,"source":{"system":"sec-edgar","filing":"0001415889-21-006174","document":"form4-12222021_101232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588921006174/form4-12222021_101232.xml","form_type":"4"}},{"id":2461264,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62302,"kind":"person","name":"Duncan Gregory Scott","position":1,"cik":"0001831127","reported_name":"Duncan Gregory Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2021-12-22T18:23:58.000Z","date":"2021-12-21","kind":"purchase","acquired":true,"shares":5000,"price":5.523,"value":27615.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.395 to $5.708, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. (\"Virios\"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":24961,"source":{"system":"sec-edgar","filing":"0001415889-21-006172","document":"form4-12222021_101249.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588921006172/form4-12222021_101249.xml","form_type":"4"}},{"id":2637130,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-09T17:36:49.000Z","date":"2021-07-07","kind":"purchase","acquired":true,"shares":942,"price":6.317,"value":5950.614,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This purchase was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include 18,201 shares that were previously reported on the reporting person's Form 3 and prior Forms 4.  Such shares were included in the person's holdings in error."}],"balance_after":710734,"source":{"system":"sec-edgar","filing":"0001415889-21-003569","document":"form4-07092021_100738.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588921003569/form4-07092021_100738.xml","form_type":"4"}},{"id":2657562,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-23T19:26:05.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":7875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 12 equal monthly installments following the grant date."}],"balance_after":7875,"derivative":{"exercise_price":6.5,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":7875},"source":{"system":"sec-edgar","filing":"0001415889-21-003158","document":"form4-06232021_120654.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588921003158/form4-06232021_120654.xml","form_type":"4"}},{"id":2657563,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93755,"kind":"person","name":"Burch Richard Alan","position":1,"cik":"0001837084","reported_name":"Burch Richard Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-23T18:59:46.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":7875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 12 equal monthly installments following the grant date."}],"balance_after":7875,"derivative":{"exercise_price":6.5,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":7875},"source":{"system":"sec-edgar","filing":"0001415889-21-003156","document":"form4-06232021_110634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588921003156/form4-06232021_110634.xml","form_type":"4"}},{"id":2657561,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":15653,"kind":"person","name":"Whitley Richard James","position":1,"cik":"0001441661","reported_name":"Whitley Richard James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-23T18:55:45.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":7875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 12 equal monthly installments following the grant date."}],"balance_after":7875,"derivative":{"exercise_price":6.5,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":7875},"source":{"system":"sec-edgar","filing":"0001415889-21-003154","document":"form4-06232021_110634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588921003154/form4-06232021_110634.xml","form_type":"4"}},{"id":2657560,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37293,"kind":"person","name":"Thomas John C","position":1,"cik":"0001424620","reported_name":"Thomas John C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-23T18:52:42.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":7875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 12 equal monthly installments following the grant date."}],"balance_after":7875,"derivative":{"exercise_price":6.5,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":7875},"source":{"system":"sec-edgar","filing":"0001415889-21-003152","document":"form4-06232021_110629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588921003152/form4-06232021_110629.xml","form_type":"4"}},{"id":2657559,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37291,"kind":"person","name":"Keefer David R","position":1,"cik":"0001825986","reported_name":"Keefer David R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-23T18:48:06.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":7875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 12 equal monthly installments following the grant date."}],"balance_after":7875,"derivative":{"exercise_price":6.5,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":7875},"source":{"system":"sec-edgar","filing":"0001415889-21-003150","document":"form4-06232021_110655.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588921003150/form4-06232021_110655.xml","form_type":"4"}},{"id":2657558,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":37292,"kind":"person","name":"De La Rosa Abel","position":1,"cik":"0001825983","reported_name":"De La Rosa Abel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-23T18:42:10.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":7875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 12 equal monthly installments following the grant date."}],"balance_after":7875,"derivative":{"exercise_price":6.5,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":7875},"source":{"system":"sec-edgar","filing":"0001415889-21-003148","document":"form4-06232021_110653.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588921003148/form4-06232021_110653.xml","form_type":"4"}},{"id":2659136,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62304,"kind":"person","name":"Walsh Angela","position":1,"cik":"0001825987","reported_name":"Walsh Angela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP OF FINANCE"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-22T21:05:01.000Z","date":"2021-06-21","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on June 21, 2022 and 1/24th monthly thereafter."}],"balance_after":30000,"derivative":{"exercise_price":6.78,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-21-003146","document":"form4-06222021_020636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588921003146/form4-06222021_020636.xml","form_type":"4"}},{"id":2659133,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62305,"kind":"person","name":"Grosswald Ralph","position":1,"cik":"0001826084","reported_name":"Grosswald Ralph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VICE PRESIDENT OF OPERATIONS"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-22T21:01:38.000Z","date":"2021-06-21","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on June 21, 2022 and 1/24th monthly thereafter."}],"balance_after":30000,"derivative":{"exercise_price":6.78,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-21-003144","document":"form4-06222021_020609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588921003144/form4-06222021_020609.xml","form_type":"4"}},{"id":2659132,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62302,"kind":"person","name":"Duncan Gregory Scott","position":1,"cik":"0001831127","reported_name":"Duncan Gregory Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-22T20:58:47.000Z","date":"2021-06-21","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests one-third on June 21, 2022 and 1/24th monthly thereafter."}],"balance_after":60000,"derivative":{"exercise_price":6.78,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-21-003142","document":"form4-06222021_010611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000141588921003142/form4-06222021_010611.xml","form_type":"4"}},{"id":2754541,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62302,"kind":"person","name":"Duncan Gregory Scott","position":1,"cik":"0001831127","reported_name":"Duncan Gregory Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-04-07T17:59:46.000Z","date":"2021-04-06","kind":"purchase","acquired":true,"shares":382,"price":6.3576,"value":2428.6032,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This purchase was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 25, 2021."}],"balance_after":19961,"source":{"system":"sec-edgar","filing":"0001104659-21-047486","document":"tm2112418-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000110465921047486/tm2112418-1_4seq1.xml","form_type":"4"}},{"id":2755924,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62302,"kind":"person","name":"Duncan Gregory Scott","position":1,"cik":"0001831127","reported_name":"Duncan Gregory Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-04-07T01:56:16.000Z","date":"2021-04-05","kind":"purchase","acquired":true,"shares":15675,"price":6.1727,"value":96757.0725,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This purchase was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 25, 2021."}],"balance_after":19579,"source":{"system":"sec-edgar","filing":"0001104659-21-047253","document":"tm2112349d1_4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000110465921047253/tm2112349d1_4a.xml","form_type":"4/A","original_submission_date":"2021-04-06"}},{"id":2755922,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62302,"kind":"person","name":"Duncan Gregory Scott","position":1,"cik":"0001831127","reported_name":"Duncan Gregory Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-04-06T19:38:39.000Z","date":"2021-04-05","kind":"purchase","acquired":true,"shares":15675,"price":6.1727,"value":96757.0725,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 25, 2021."}],"balance_after":19579,"source":{"system":"sec-edgar","filing":"0001104659-21-047069","document":"tm2112297-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000110465921047069/tm2112297-1_4.xml","form_type":"4"}},{"id":2888889,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":62304,"kind":"person","name":"Walsh Angela","position":1,"cik":"0001825987","reported_name":"Walsh Angela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Finance"}}],"security":"Common Stock","published_at":"2021-02-02T00:54:40.000Z","date":"2021-01-28","kind":"purchase","acquired":true,"shares":1000,"price":7.3,"value":7300.0,"ownership":{"direct":false,"nature":"By IRA"},"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001104659-21-010387","document":"tm214953-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000110465921010387/tm214953-3_4seq1.xml","form_type":"4"}},{"id":2888888,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2021-02-02T00:54:25.000Z","date":"2021-01-28","kind":"exercise","acquired":false,"shares":801,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"The Reporting Person provided notice of exercise to the Issuer on January 20, 2021 and the Company authorized the issuance of the shares pursuant to such exercise on January 28, 2020."}],"balance_after":0,"derivative":{"exercise_price":7.8,"exercise_date":"2020-12-16","expiration_date":"2021-01-20","underlying":"Common Stock","underlying_shares":801},"source":{"system":"sec-edgar","filing":"0001104659-21-010386","document":"tm214953-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000110465921010386/tm214953-2_4seq1.xml","form_type":"4"}},{"id":2888887,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-02T00:54:25.000Z","date":"2021-01-29","kind":"purchase","acquired":true,"shares":3500,"price":7.47,"value":26145.0,"ownership":{"direct":false,"nature":"401(k) Account"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee."}],"balance_after":3500,"source":{"system":"sec-edgar","filing":"0001104659-21-010386","document":"tm214953-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000110465921010386/tm214953-2_4seq1.xml","form_type":"4"}},{"id":2888886,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":93756,"kind":"person","name":"Pridgen William","position":1,"cik":"0001826115","reported_name":"Pridgen William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-02T00:54:25.000Z","date":"2021-01-28","kind":"exercise","acquired":true,"shares":801,"price":7.8,"value":6247.8,"ownership":{"direct":true},"balance_after":727993,"source":{"system":"sec-edgar","filing":"0001104659-21-010386","document":"tm214953-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000110465921010386/tm214953-2_4seq1.xml","form_type":"4"}}],"next_cursor":"2021-02-02T00:54:25.000000Z,2888886"}